- NEGATIVE
Quarterly Revenue United Therapeutics Corp Jun-2026 Quarterly Revenue is $783 Million which is growth of -1.9% YoY.
- POSITIVE
Quarterly Net Profit United Therapeutics Corp Jun-2026 Quarterly Net Profit is $333 Million which is growth of 7.6% YoY.
532.78-12.22(-2.24%)
1.4M
XNAS Volume
XNAS 08 Oct, 2026 5:30 PM (EDT)
United Therapeutics Corp quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for United Therapeutics Corp share price target, revenues, EPS, net income and more
United Therapeutics Corp quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | 783.3 | 781.5 | 790.2 | 799.5 | 798.6 | 794.4 | 735.9 | 748.9 | 714.9 | 677.7 | 614.7 | 609.4 | 596.5 | |
Cost Of Rev. | 99.5 | 133.4 | 103.4 | 100.9 | 87.6 | 92.5 | 75.9 | 83.1 | 77.8 | 72.9 | 71 | 70.1 | 64.1 | |
Gross Profit | 683.8 | 648.1 | 686.8 | 698.6 | 711 | 701.9 | 660 | 665.8 | 637.1 | 604.8 | 543.7 | 539.3 | 532.4 | |
| 353 | 322.3 | 329.3 | 309.3 | 324.8 | 319.1 | 296.3 | 257.6 | 317.2 | 248.5 | 283.6 | 212.3 | 219 | ||
Operating Profit | 330.8 | 325.8 | 357.5 | 389.3 | 386.2 | 382.8 | 363.7 | 408.2 | 319.9 | 356.3 | 260.1 | 327 | 313.4 | |
| 28.6 | 38.8 | 40.1 | 43.4 | 44 | 45 | 41.4 | 39.7 | 34.6 | 40.5 | 35.9 | 29.7 | 22.4 | ||
Profit Before Tax | 372.7 | 318.3 | 444 | 438 | 408.4 | 423.5 | 396.5 | 388.6 | 355.3 | 398.6 | 295.4 | 351.8 | 335.2 | |
Tax | 39.7 | 43.4 | 79.7 | 99.3 | 98.9 | 101.3 | 95.2 | 79.5 | 77.2 | 92 | 78.3 | 84.2 | 76 | |
| 333 | 274.9 | 364.3 | 338.7 | 309.5 | 322.2 | 301.3 | 309.1 | 278.1 | 306.6 | 217.1 | 267.6 | 259.2 | ||
Diluted NI Avail to Com Stockholders Ann. | 333 | 274.9 | 364.3 | 338.7 | 309.5 | 322.2 | 301.3 | 309.1 | 278.1 | 306.6 | 217.1 | 267.6 | 259.2 | |
Basic EPS | 7.8 | 6.3 | 8.4 | 7.7 | 6.9 | 7.2 | 6.7 | 6.9 | 6.3 | 6.5 | 4.6 | 5.7 | 5.5 | |
Diluted EPS After ExtraOrdinary | 7.3 | 5.8 | 7.7 | 7.2 | 6.8 | 6.6 | 6.3 | 7.5 | 5.9 | 6.2 | 4.4 | 5.4 | 5.2 | |
Number Of Shares End | 42.6 | 43.5 | 43.4 | 43.8 | 45.1 | 44.9 | 44.9 | 44.6 | 44.4 | 47 | 47.1 | 46.9 | 46.9 | |
Net Income Continuing Discontinued Operations | 333 | 274.9 | 364.3 | 338.7 | 309.5 | 322.2 | 301.3 | 309.1 | 278.1 | 306.6 | 217.1 | 267.6 | 259.2 | |
Normalized Income | 333 | 274.9 | 365 | 339.3 | 326 | 322.2 | 305.9 | 360.9 | 278.1 | 306.6 | 217.1 | 267.6 | 259.2 | |
Interest Income | 31.5 | 41.8 | 43.2 | 46.4 | 51.3 | 51.1 | 49.3 | 49.8 | 46.2 | 53.8 | 51 | 45.3 | 37.2 | |
Interest | 2.9 | 3 | 3.1 | 3 | 7.3 | 6.1 | 7.9 | 10.1 | 11.6 | 13.3 | 15.1 | 15.6 | 14.8 | |
Net Interest Income | 28.6 | 38.8 | 40.1 | 43.4 | 44 | 45 | 41.4 | 39.7 | 34.6 | 40.5 | 35.9 | 29.7 | 22.4 | |
EBIT | 375.6 | 321.3 | 447.1 | 441 | 415.7 | 429.6 | 404.4 | 398.7 | 366.9 | 411.9 | 310.5 | 367.4 | 350 | |
EBITDA | 399.8 | 343.9 | 469.9 | 462.9 | 436.8 | 449.4 | 424.1 | 417.8 | 385.6 | 426.9 | 324.2 | 380.7 | 362.9 | |
Reconciled Cost Of Rev. | 99.5 | 133.4 | 103.4 | 100.9 | 87.6 | 92.5 | 75.9 | 83.1 | 77.8 | 72.9 | 71 | 70.1 | 64.1 | |
Reconciled Depr. | 24.2 | 22.6 | 22.8 | 21.9 | 21.1 | 19.8 | 19.7 | 19.1 | 18.7 | 15 | 13.7 | 13.3 | 12.9 | |
Profit From Continuing Operations | 333 | 274.9 | 364.3 | 338.7 | 309.5 | 322.2 | 301.3 | 309.1 | 278.1 | 306.6 | 217.1 | 267.6 | 259.2 | |
Normalized EBITDA | 399.8 | 343.9 | 470.7 | 463.7 | 458.5 | 449.4 | 430.1 | 482.9 | 385.6 | 426.9 | 324.2 | 380.7 | 362.9 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
United Therapeutics Corp competitor comparison and performance snapshot within industry
United Therapeutics Corp annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue United Therapeutics Corp Dec-2025 Annual Revenue is $3,183 Million which is growth of 10.6% YoY.
- POSITIVE
Annual Net Profit United Therapeutics Corp Dec-2025 Annual Net Profit is $1,335 Million which is growth of 11.7% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
18% | 16.5% | 3,182.7 | 2,877.4 | 2,327.5 | 1,936.3 | 1,685.5 | 1,483.3 | 1,448.8 | 1,627.8 | 1,725.3 | 1,598.8 | 1,465.8 | |||
Cost Of Rev. Ann. | 36.4% | 28.9% | 437.2 | 384.4 | 309.7 | 257.5 | 151.6 | 122.5 | 108.1 | 117.6 | 198.7 | 105.7 | 72.7 | 69 | |
Gross Profit Ann. | 16.2% | 15.3% | 2,717.3 | 2,798.3 | 2,567.7 | 2,070 | 1,784.7 | 1,563 | 1,375.2 | 1,331.2 | 1,429.1 | 1,619.6 | 1,526.1 | 1,396.7 | |
Operating Exp. Ann. | 16.8% | 10.4% | 1,313.9 | 1,281.1 | 1,119.6 | 885.1 | 805 | 1,007.1 | 781.6 | 1,518.8 | 623.7 | 594.7 | 464.4 | 697.7 | |
Operating Profit Ann. | 15.7% | 20.6% | 1,403.4 | 1,517.2 | 1,448.1 | 1,184.9 | 979.7 | 555.9 | 593.6 | -187.6 | 805.4 | 1,024.9 | 1,061.7 | 699 | |
138% | 102.2% | 150.9 | 172.5 | 156.2 | 103.4 | 12.8 | -1.9 | 5.1 | 14.7 | -9 | -3.9 | -4.7 | |||
Other Exp. Ann. | - | -9.7% | 24.2 | -65.3 | -14 | -41.9 | 39.9 | 40.2 | 22.6 | -61.2 | -246.4 | 2.4 | 350.2 | ||
PBT Ann. | 21.7% | 21.8% | 1,573 | 1,713.9 | 1,539 | 1,274.3 | 950.6 | 593.9 | 638.9 | -165 | 758.9 | 769.5 | 1,060.2 | 1,044.4 | |
Tax Ann. | 19.3% | 25% | 262.1 | 379.2 | 343.9 | 289.5 | 223.3 | 118.1 | 124.1 | -60.5 | 169.7 | 351.6 | 346.5 | 392.8 | |
22.4% | 21% | 1,310.9 | 1,334.7 | 1,195.1 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | 589.2 | 417.9 | 713.7 | 651.6 | ||
Diluted NI Avail to Com Stockholders Ann. | 22.4% | 21% | 1,310.9 | 1,334.7 | 1,195.1 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | 589.2 | 417.9 | 713.7 | 651.6 | |
EPS Ann. | 23.4% | 20.8% | 30.1 | 26.4 | 21 | 16 | 10.6 | 11.7 | -2.4 | 13.5 | 9.5 | 16.3 | 14.2 | ||
Diluted EPS Ann. | 23% | 19.4% | 27.9 | 24.6 | 19.8 | 15 | 10.1 | 11.5 | -2.4 | 13.4 | 9.3 | 15.3 | 12.7 | ||
Number Of Shares End | -2% | -0.5% | 43.4 | 44.9 | 47.1 | 46.1 | 45.2 | 44.5 | 43.8 | 43.5 | 43.1 | 42.3 | 45.7 | ||
Total Exp. Ann. | 20.3% | 13.4% | 1,665.5 | 1,429.3 | 1,142.6 | 956.6 | 1,129.6 | 889.7 | 1,636.4 | 822.4 | 700.4 | 537.1 | 766.8 | ||
Net Income Continuing Discontinued Operations Ann. | 22.4% | 21% | 1,310.9 | 1,334.7 | 1,195.1 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | 589.2 | 417.9 | 713.7 | 651.6 | |
Normalized Income Ann. | 22.9% | 21% | 1,312.2 | 1,353.9 | 1,250.6 | 984.8 | 728.6 | 477.6 | 522.2 | -104.5 | 630.9 | 573.7 | 713.7 | 434.6 | |
Interest Income Ann. | 62% | 46.3% | 162.9 | 192 | 199.1 | 162.7 | 45.2 | 16.7 | 28.6 | 44.2 | 28.6 | - | - | - | |
Interest Ann. | -15.6% | -3.7% | 12 | 19.5 | 42.9 | 59.3 | 32.4 | 18.6 | 23.5 | 44.2 | 13.9 | 9 | 3.9 | 4.7 | |
EBITDA Ann. | 20.7% | 20.6% | 1,676.5 | 1,819 | 1,654.4 | 1,386.8 | 1,034.3 | 662.4 | 712.3 | -74.9 | 808.7 | 809.5 | 1,095.7 | 1,082.1 | |
Reconciled Cost Of Rev. Ann. | 36.4% | 28.9% | 437.2 | 384.4 | 309.7 | 257.5 | 151.6 | 122.5 | 108.1 | 117.6 | 198.7 | 105.7 | 72.7 | 69 | |
Reconciled Depr. Ann. | 18.6% | 11.4% | 91.5 | 85.6 | 72.5 | 53.2 | 51.3 | 49.9 | 49.9 | 45.9 | 35.9 | 31 | 31.6 | 32.9 | |
Profit From Continuing Operations Ann. | 22.4% | 21% | 1,310.9 | 1,334.7 | 1,195.1 | 984.8 | 727.3 | 475.8 | 514.8 | -104.5 | 589.2 | 417.9 | 713.7 | 651.6 | |
Normalized EBITDA Ann. | 21.2% | 20.6% | 1,678.1 | 1,843.7 | 1,725.5 | 1,386.8 | 1,036 | 664.7 | 721.4 | -74.9 | 862.2 | 1,069.1 | 1,095.7 | 732.1 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
10.6%
2Y CAGR
16.9%
3Y CAGR
18%
5Y CAGR
16.5%
7Y CAGR
10.1%
10Y CAGR
8.1%
Total Revenue Annual growth is stable compared to historical averages.
Net Profit Ann.
1Y CHG
11.7%
2Y CAGR
16.4%
3Y CAGR
22.4%
5Y CAGR
21%
7Y CAGR
12.4%
10Y CAGR
7.4%
Net Profit Annual growth is lower than historical averages.
Operating Exp. Ann.
1Y CHG
14.4%
2Y CAGR
20.3%
3Y CAGR
16.8%
5Y CAGR
10.4%
7Y CAGR
10.8%
10Y CAGR
6.3%
Operating Expenses Annual Cr growth is stable compared to historical averages.
United Therapeutics Corp balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund United Therapeutics Corp Dec-2025 Total Shareholders Fund is $7,096 Million which is growth of 10.1% YoY.
- POSITIVE
Total Assets United Therapeutics Corp Dec-2025 Total Assets is $7,880 Million which is growth of 7.0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9.2% | 11.3% | 7,880 | 7,364 | 7,167 | 6,044.5 | 5,169.1 | 4,615 | 3,913.4 | 3,401 | 2,879.4 | 2,325.6 | 2,184.4 | ||
-14.4% | -8.5% | 783.8 | 920 | 1,182.2 | 1,247.8 | 1,210.2 | 1,219.8 | 1,133 | 593.2 | 758.4 | 463.4 | 584.8 | ||
13.9% | 15.9% | 7,096.2 | 6,444 | 5,984.8 | 4,796.7 | 3,958.9 | 3,395.2 | 2,780.4 | 2,788.6 | 2,101.8 | 1,851.3 | 1,588.6 | ||
Total Capitalization Ann. | 8.2% | 11.1% | 7,096.2 | 6,444 | 6,284.8 | 5,596.7 | 4,758.9 | 4,195.2 | 3,380.4 | 3,057.8 | 2,371 | 1,862.2 | 1,599.7 | |
Tangible Assets Ann. | 13.7% | 16.6% | 6,979.7 | 6,332.1 | 5,870.6 | 4,752.2 | 3,914.3 | 3,237.1 | 2,622.1 | 2,637 | 2,075.4 | 1,828.4 | 1,571.3 | |
Working Capital Ann. | 1.1% | 11.2% | 3,141.9 | 3,135.8 | 2,746.6 | 3,037.1 | 2,018.2 | 1,843.9 | 1,401.5 | 1,491.4 | 1,003.2 | 1,092.3 | 834.5 | |
Invested Capital Ann. | 8.2% | 11.1% | 7,096.2 | 6,744 | 6,684.8 | 5,596.7 | 4,758.9 | 4,195.2 | 3,630.4 | 3,038.6 | 2,351.8 | 1,851.3 | 1,593.9 | |
Tangible Book Value Ann. | 13.7% | 16.6% | 6,979.7 | 6,332.1 | 5,870.6 | 4,752.2 | 3,914.3 | 3,237.1 | 2,622.1 | 2,617.8 | 2,056.2 | 1,817.5 | 1,560.2 | |
Borrowings Ann. | - | - | - | 300 | 700 | 800 | 800 | 800 | 850 | 250 | 250 | - | 5.4 | |
Net Debt Ann. | - | - | - | - | - | - | - | 61.3 | 111.6 | - | - | - | - | |
Share Issued Ann. | 1.7% | 1.5% | 76.5 | 75 | 73.7 | 72.7 | 71.7 | 71.1 | 70.5 | 70.2 | 69.9 | 69.3 | 69 | |
Number Of Shares End | -2% | -0.5% | 43.4 | 44.9 | 47.1 | 46.1 | 45.2 | 44.5 | 43.8 | 43.5 | 43.1 | 42.3 | 45.7 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
7%
2Y CAGR
4.9%
3Y CAGR
9.2%
5Y CAGR
11.3%
7Y CAGR
12.8%
10Y CAGR
13.7%
Total Assets Annual growth is lower than historical averages.
Total Current Liabilities Ann.
1Y CHG
-24%
2Y CAGR
-16.5%
3Y CAGR
17.8%
5Y CAGR
11.6%
7Y CAGR
10.6%
10Y CAGR
2.4%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
10.1%
2Y CAGR
8.9%
3Y CAGR
13.9%
5Y CAGR
15.9%
7Y CAGR
14.3%
10Y CAGR
16.1%
Total ShareHolders Funds Annual growth is lower than historical averages.
United Therapeutics Corp ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share United Therapeutics Corp Book Value Per Share is $149 which is growth of -5.9% YoY.
- NEUTRAL
ROE United Therapeutics Corp ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | 16.45% | 14.91% | 12.97% | 9.73% | 12.07% | -2.86% | 18.76% | 16.06% | 31.65% | 32.03% | |
ROE Ann. % | - | - | - | 19.23% | 18.27% | 16.61% | 12.94% | 16.67% | -3.75% | 24.10% | 21.14% | 41.50% | 46.04% | |
ROIC % | - | - | - | 4.1 | 2.9 | 2.3 | 2.4 | 2.4 | 1.4 | 2.1 | 0.9 | 6.1 | 6.8 | |
OPM Ann. % | -2% | 3.6% | 47.67% | 50.33% | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 59.40% | 66.41% | 47.69% | |
Inventory Turnover Ratio Ann. | - | - | - | 2.3 | 2.4 | 1.6 | 1.4 | 1.2 | 1.2 | 1.9 | 1 | 0.8 | 0.9 | |
Asset Turnover Ann. % | - | - | - | 0.4 | 0.4 | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | 0.7 | 0.7 | 0.7 | |
Working Capital Turnover Ann. | 18.6% | 4.6% | 1 | 0.9 | 0.9 | 0.6 | 0.8 | 0.8 | 1 | 1.1 | 1.7 | 1.5 | 1.8 | |
Quick Ratio Ann. | - | - | - | 4.8 | 4.1 | 8.9 | 7 | 6.2 | 3.5 | 5.8 | 2.8 | 3.8 | 2.6 | |
Current Ratio Ann. | - | - | - | 5.3 | 4.4 | 9.9 | 7.6 | 6.7 | 4 | 6.4 | 3.3 | 4.3 | 2.9 | |
Interest Coverage Ratio Ann. | - | - | - | 36.9 | 22.5 | 30.3 | 32.9 | 28.2 | -2.7 | 55.6 | 86.5 | 272.9 | 221.6 | |
LT Debt To Equity Ann. | - | - | - | - | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
United Therapeutics Corp cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity United Therapeutics Corp Dec-2025 Cash From Operating Activity is $1,561 Million which is growth of 17.6% YoY.
- NEGATIVE
Net Cash Flow United Therapeutics Corp Dec-2025 Net Cash Flow is $-140 Million which is growth of -128.6% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
24.8% | 15.6% | 1,561.2 | 1,327.1 | 978 | 802.5 | 598.2 | 755.7 | -206.6 | 778.4 | 474.2 | 643.6 | 382.8 | ||
- | - | -551.3 | 417.2 | -719.6 | -811.5 | -486.9 | -738.5 | -335.4 | -820.6 | -835.6 | 48.3 | 503.6 | ||
- | - | -1,150 | -1,254.8 | -11.9 | 75.4 | 44.8 | -16.9 | 611.2 | 6.3 | 43.3 | -497.7 | -446.9 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 17.4% | 16.1% | 1,557.1 | 1,697.2 | 1,207.7 | 961.2 | 894.8 | 738.7 | 738.4 | 669.2 | 705.1 | 1,023 | 831.8 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | - | -140.1 | 489.5 | 246.5 | 66.4 | 156.1 | 0.3 | 69.2 | -35.9 | -318.1 | 194.2 | 439.4 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | 23.8% | 18.1% | 1,697.2 | 1,207.7 | 961.2 | 894.8 | 738.7 | 738.4 | 669.2 | 705.1 | 1,023 | 831.8 | 397.7 | |
Income Tax Paid Supplemental Data Ann. | 4.4% | 27.6% | 313.3 | 400.6 | 332.5 | 275.7 | 153.3 | 92.8 | 120.2 | 102.7 | 346.9 | 362.4 | 293.3 | |
Interest Paid Supplemental Data Ann. | -22.6% | -8.2% | 13.5 | 40.2 | 56 | 29.1 | 16.2 | 20.7 | 41 | 9.4 | 7.5 | 1.5 | 1 | |
Capex Ann. | - | - | -526 | -246.5 | -230.4 | -138.8 | -120.8 | -59.3 | -83.7 | -184.4 | -86.3 | -43.2 | -49.8 | |
Issuance Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Issuance Of Debt Ann. | -37% | - | 200 | 800 | 800 | 250 | 250 | - | ||||||
Repayment Of Debt Ann. | - | - | -500 | -400 | -100 | -800 | -50 | -200 | -250 | -8.8 | -133.2 | |||
Repurchase Of Capital Stock Ann. | - | - | -1,016.6 | -1,012.2 | -13.8 | -11.4 | -10.8 | -3.7 | -2.1 | - | -250 | -500 | -394.5 | |
Free Cash Flow Ann. | 16% | 8.3% | 1,035.2 | 1,080.6 | 747.6 | 663.7 | 477.4 | 696.4 | -290.3 | 594 | 387.9 | 600.4 | 333 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
17.6%
2Y CAGR
26.3%
3Y CAGR
24.8%
5Y CAGR
15.6%
7Y CAGR
10.5%
10Y CAGR
15.1%
Cash from Operating Activity Annual growth is stable compared to historical averages.